Skip to main content
Top
Published in: International Journal of Diabetes in Developing Countries 3/2017

01-09-2017 | Editorial

Hypogonadism and diabetes mellitus - Implications for cardiovascular risk

Author: Madhu SV

Published in: International Journal of Diabetes in Developing Countries | Issue 3/2017

Login to get access

Excerpt

It is well recognized that hypogonadism is common in diabetes mellitus (DM) [13]. However, most of the earlier reports have been in the context of sexual dysfunction particularly resulting in erectile dysfunction (ED) in diabetic men [2]. While ED is an important cause of morbidity in these individuals, there could be other health consequences that also require urgent attention. Testosterone deficiency can affect several facets of the well-being of diabetic patients including sexual performance, mental health, and quality of life [4]. More recently, studies have also focussed on issues that could impact the cardiovascular (CV) and bone health of those affected with DM. Several studies have suggested that hypogonadism particularly in diabetic men is associated with insulin resistance (IR) [5] and a higher occurrence of metabolic syndrome [6]. Clamp studies in patients of DM with testosterone deficiency have revealed a significant reduction in insulin-mediated glucose uptake that has been shown to improve with gonadal hormone replacement in these hypogonadal individuals [7]. These observations suggest that hypogonadism could be associated with significant CV risk among diabetic subjects. …
Literature
1.
go back to reference Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30:911–7.CrossRefPubMed Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30:911–7.CrossRefPubMed
2.
go back to reference Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 2006;18:190–7.CrossRefPubMed Corona G, Mannucci E, Petrone L, Ricca V, Balercia G, Mansani R, et al. Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res. 2006;18:190–7.CrossRefPubMed
3.
go back to reference Dandona P, Dhindsa S, Chandel A, Chaudhuri A. Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgraduate Med. 2009;125:45–51.CrossRef Dandona P, Dhindsa S, Chandel A, Chaudhuri A. Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgraduate Med. 2009;125:45–51.CrossRef
4.
go back to reference Jones TH. Testosterone associations with erectile dysfunction, diabetes and the metabolic syndrome. Eur Urol Suppl. 2007;6:847–57.CrossRef Jones TH. Testosterone associations with erectile dysfunction, diabetes and the metabolic syndrome. Eur Urol Suppl. 2007;6:847–57.CrossRef
5.
go back to reference Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005;28(7):1636–42.CrossRefPubMed Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, Eriksson KF, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care. 2005;28(7):1636–42.CrossRefPubMed
7.
go back to reference Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39:82–91.CrossRefPubMed Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39:82–91.CrossRefPubMed
8.
go back to reference Madhu SV, Aslam M, Aiman AJ, Siddiqui A, Dwivedi S. Prevalence of hypogonadism in male type 2 diabetes mellitus patients with and without coronary artery disease. Indian J Endocr Metab. 2017;21:31–7.CrossRef Madhu SV, Aslam M, Aiman AJ, Siddiqui A, Dwivedi S. Prevalence of hypogonadism in male type 2 diabetes mellitus patients with and without coronary artery disease. Indian J Endocr Metab. 2017;21:31–7.CrossRef
9.
go back to reference Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata C, et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care. 2003;26:1869–73.CrossRefPubMed Fukui M, Kitagawa Y, Nakamura N, Kadono M, Mogami S, Hirata C, et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care. 2003;26:1869–73.CrossRefPubMed
10.
go back to reference Seidell JC, Björntorp P, Sjöström L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897–901.CrossRefPubMed Seidell JC, Björntorp P, Sjöström L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39:897–901.CrossRefPubMed
12.
go back to reference Svartberg J, von Mühlen D, Mathiesen E, Joakimsen O, Bønaa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259:576–82.CrossRefPubMed Svartberg J, von Mühlen D, Mathiesen E, Joakimsen O, Bønaa KH, Stensland-Bugge E. Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med. 2006;259:576–82.CrossRefPubMed
13.
go back to reference Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation. 1995;91:1154–60.CrossRefPubMed Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation. 1995;91:1154–60.CrossRefPubMed
15.
go back to reference Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.CrossRefPubMed Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.CrossRefPubMed
16.
go back to reference Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30:726–33.CrossRefPubMed Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30:726–33.CrossRefPubMed
17.
go back to reference Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15.CrossRefPubMed Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15.CrossRefPubMed
18.
go back to reference Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinology. 2013;169:725–33.CrossRef Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinology. 2013;169:725–33.CrossRef
Metadata
Title
Hypogonadism and diabetes mellitus - Implications for cardiovascular risk
Author
Madhu SV
Publication date
01-09-2017
Publisher
Springer India
Published in
International Journal of Diabetes in Developing Countries / Issue 3/2017
Print ISSN: 0973-3930
Electronic ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-017-0573-2

Other articles of this Issue 3/2017

International Journal of Diabetes in Developing Countries 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.